- Home
- About Us
-
Investment Banking
- Equity Research
- Careers
- Contact
Equity Research
Rodman & Renshaw’s team of Research Analysts have achieved an enviable record of identifying compelling investment opportunities among undiscovered and undervalued companies. The Research Staff follows both industry leaders and emerging companies across a variety of sectors.
Our Team’s thoughtful research empowers a broad variety of Institutional Investors, including the world’s largest Asset Managers and Sector-dedicated Specialists throughout the U.S., Europe, Asia, and beyond.
Driven by Ph.D.s and industry veterans, the Rodman Research Team understands both the business rationale and sector-specific dynamics around a value proposition – offering a comrehensive and competitive perspective. The Team’s work has been well-recognized across the Wall Street Journal, Financial Times, Institutional Investor, and other leading publications.
Our Team
Tony Butler
Following a fellowship at the Rockefeller University, Tony was the first biotechnology analyst at Raymond James beginning in 1992. He subsequently spent several years at Lehman Brothers, Barclays Capital, and Guggenheim. At Lehman Brothers/Barclays Capital, Dr. Butler was one of the top-ranked equity research analysts for over a decade, including #1 according to Institutional Investor. 2024 marks Dr. Butler’s 32nd year on Wall Street.
Elemer Piros
Elemer has over 24 years of experience in biotechnology research. Prior to Rodman & Renshaw, he served as Managing Director, Senior Biotechnology Analyst at ROTH Capital Partners. Prior to his tenure at ROTH, Dr. Piros served as Managing Director and Senior Biotechnology Analyst at Cantor Fitzgerald, Burrill & Company, and Rodman & Renshaw. Dr. Piros was ranked as #1 Biotechnology analyst by the Wall Street Journal in 2007 and by the Financial Times in 2010, both based on stock portfolio performance. Dr. Piros received his Ph.D. in Neuroscience from University of California, Los Angeles.
Brandon Folkes
Brandon has over 11 years of experience in biopharma and biotechnology equity research. Prior to Rodman & Renshaw, he served as Managing Director, Equity Research at Cantor Fitzgerald. Prior to his tenure at Cantor, Mr. Folkes held equity research positions at Guggenheim Partners and CRT Capital. Before joining Wall Street, Mr. Folkes held positions at KPMG and PwC in the U.S., South Africa, and British Virgin Islands. Mr. Folkes holds degrees from Stellenbosch University and The University of South Africa; and has obtained his CFA and Chartered Accountancy designations.
Coverage List
